David Wallace

West Midlands

Executive Editor at Generics Bulletin

Generics Bulletin editor Dave Wallace looks at everything that's important to the generics, biosimilars and value-added medicines industries. All views my own.

Featured in: Favicon

informa.com (+2) Favicon

citeline.com (+1)

Articles

Telmisartan Leads UK Rises In September As Price Surges Subside

Oct 14, 2024 | generics.citeline.com | David Wallace

Data Executive Summary September saw the extreme price rises of the last few months subside in the UK, albeit still seeing a handful of treble-digit percentage average increases for products like telmisartan.
Sandoz, Adalvo And Eurofarma Celebrate Multiple Wins At GGB Awards

Oct 9, 2024 | generics.citeline.com | David Wallace

News Executive Summary Sandoz, Adalvo and Eurofarma were the biggest winners at the Global Generics & Biosimilars Awards 2024, each taking multiple honors, among the many champions named across 14 separate categories at our prizegiving ceremony in Milan.
‘There Is No Silver Bullet’ - Sandoz’s Haruvi Talks US Shortages

Oct 7, 2024 | pink.citeline.com | David Wallace

Interviews Executive Summary As Sandoz publishes a report on US drug shortages, including a call for policy and other improvements, the firm’s North America head and AAM Chair Keren Haruvi discussed potential solutions to ongoing supply-chain failures. Source: Shutterstock Existing Subscriber? Sign in to continue reading. New to Pink Sheet? Start a free trial today!
‘Quiet Giant’ Biocon Sets Out Vision For Biosimilars

Oct 6, 2024 | generics.citeline.com | David Wallace

Interviews Executive Summary Biocon Biologics chief commercial officer for advanced markets Matt Erick says the firm is a “quiet giant” in the biosimilars space, but speaks up about the firm’s plans to grow its business in Europe, explore in-licensing as well as in-house development, and capitalize on the upcoming loss of exclusivity for Stelara in the US. Source: Biocon It has been a busy year for Biocon Biologics.
Aspire Bolsters Dermatology With Canute Acquisition

Oct 6, 2024 | generics.citeline.com | David Wallace

News Executive Summary Aspire Pharma has bolstered its dermatology portfolio by striking a deal to acquire “all assets” of another UK-based player, Canute Pharma. Source: Shutterstock Existing Subscriber? Sign in to continue reading. New to Generics Bulletin? Request a free trial today!
‘There Is No Silver Bullet’ - Sandoz’s Haruvi Talks US Shortages

Oct 3, 2024 | generics.citeline.com | David Wallace

Interviews Executive Summary As Sandoz publishes a report on US drug shortages – dissecting their root causes, the current policy landscape and recommendations for future improvements – the firm’s North America head and AAM chair Keren Haruvi speaks to Generics Bulletin about what can be done to alleviate continuing supply-chain failures. Source: Shutterstock Existing Subscriber? Sign in to continue reading.
Aeon Plans For Next Phase In Bid For Botox Biosimilar

Oct 3, 2024 | generics.citeline.com | David Wallace

News Executive Summary Aeon Biopharma has heralded its latest interaction with the US FDA over its planned Botox biosimilar as a win that sets the stage for analytical studies, trials and a subsequent filing. Source: Shutterstock Existing Subscriber? Sign in to continue reading. New to Generics Bulletin? Request a free trial today!
Organon And Henlius Advance Perjeta Biosimilar

Sep 30, 2024 | generics.citeline.com | David Wallace

News Executive Summary Organon and Henlius have marked progress on their partnered HLX11 pertuzumab candidate, with the proposed biosimilar to Perjeta meeting the primary endpoint in a Phase III trial. Source: Shutterstock Existing Subscriber? Sign in to continue reading. New to Generics Bulletin? Request a free trial today!
Stelara Biosimilar Nods Arrive In US And EU For Fresenius And Formycon

Sep 30, 2024 | generics.citeline.com | David Wallace

News Executive Summary Fresenius and Formycon have celebrated simultaneous US and EU approvals for the firms’ partnered Otulfi ustekinumab rival to Stelara. And with competing biosimilars already available on the European market, all eyes will soon be on US launches at the start of 2025, with Fresenius providing a significant update on launch timing.
Biocon Targets GLP-1s In MENA With Tabuk Tie-Up

Sep 30, 2024 | generics.citeline.com | David Wallace

News Executive Summary Biocon has struck a deal that will see its GLP-1 diabetes and chronic weight management products commercialized in the Middle East region by partner Tabuk Pharmaceutical. Source: Shutterstock Existing Subscriber? Sign in to continue reading. New to Generics Bulletin? Request a free trial today!